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ABSTRACT 46 
Hematopoietic stem cell transplantation (HSCT) is an established procedure for many 47 
acquired and congenital disorders of the hematopoietic system.  48 
A record number of 42’171 HSCT in 37’626 patients [16’030 allogeneic (43%), 21’596 49 
autologous (57%)] were reported by 655 centers in 48 countries in 2015. Trends include 50 
continued growth in transplant activity over the last decade, with the highest percentage 51 
increase seen in middle income countries but the highest absolute growth in the very high 52 
income countries in Europe. Main indications for HSCT were myeloid malignancies 9’413 53 
(25%; 96 % allogeneic); lymphoid malignancies 24’304 (67%; 20% allogeneic); solid tumors 54 
1’516 (4%; 3% allogeneic); and non-malignant disorders 2’208 (6%; 90% allogeneic). 55 
Remarkable is decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 56 
in 2015, most likely due to new drugs. Use of haploidentical donors for allogeneic HSCT 57 
continues to grow: 2’012 in 2015, a 291% increase since 2005. Growth is seen for all 58 
diseases. In AML, haploidentical HSCT increases similarly for patients with advanced 59 
disease and for those in CR1. Both marrow and peripheral blood is used as stem cell source 60 
for haploidentical HSCT with higher numbers reported for the latter. 61 
 62 
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INTRODUCTION  70 
Hematopoietic stem cell transplantation (HSCT) is an established procedure for many 71 
acquired and congenital disorders of the hematopoietic system, including disorders of the 72 
immune system, and as enzyme replacement in metabolic disorders (1-4). The annual 73 
activity survey of the European Society of Blood and Marrow Transplantation (EBMT), 74 
describing the status of HSCT in Europe and affiliated countries, has become an instrument 75 
used to observe trends and to monitor changes in technology use (5-12). The survey 76 
captures the numbers of HSCT performed in the preceding year from each participating 77 
team, divided by indication, donor type and stem cell source. The standardized structure of 78 
the survey over many years and the excellent commitment of the participating teams allow us 79 
to observe changes over time and to evaluate factors associated with these changes.  More 80 
recently, the survey has included additional information on novel cell therapies with 81 
hematopoietic stem cells for non-hematopoietic use, as well as on the use of non-82 
hematopoietic stem and progenitor cells.  This coincides with the recent interest of the World 83 
Health Organization WHO (www.who.org) in cell and tissue transplants and further stresses 84 
the need for adequate and timely information (13).  The analysis of the survey data spanning 85 
over 25 years and amassing data on more than 600'000 transplants in over 550’000 patients, 86 
has shown a continued and constant increase in the annual numbers of HSCT and transplant 87 
rates (number of HSCT/10 million inhabitants) for both allogeneic and autologous HSCT.  88 
This report is based on the 2015 survey data. In addition to transplant rates and indications, 89 
this report focuses on the use of haploidentical donors for transplantation including disease 90 
entities and stem cell source. 91 
 92 
PATIENTS AND METHODS 93 
Data collection and validation 94 
Participating teams were invited to report data for 2015 by indication, stem cell source and 95 
donor type as listed in table 1.  The survey allows the possibility to report additional 96 
information on the numbers of subsequent transplants performed as a result of relapse, 97 
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rejection or those that are part of a planned sequential transplant protocol.  Supplementary 98 
information on the numbers of donor lymphocyte infusions, reduced intensity HSCT and the 99 
numbers of pediatric HSCT is also collected.  New in this year’s survey is the more detailed 100 
report on cellular therapies (table 2). Quality control measures included several independent 101 
systems: confirmation of validity of the entered data by the reporting team, selective 102 
comparison of the survey data with MED-A data sets in the EBMT Registry database and 103 
cross-checking with the National Registries. 104 
 105 
Teams 106 
687 centers from 48 countries were contacted for the 2015 survey (39 European and 9 107 
affiliated countries); of which 655 teams reported. This corresponds to a 95% return rate and 108 
includes 552 active EBMT member teams. 32 active teams failed to report in 2015. 109 
Contacted teams are listed in the online appendix in alphabetical order by country, city and 110 
EBMT centre code, with their reported numbers of first and total HSCT, and of first allogeneic 111 
and autologous HSCT as supplementary material.  The WHO regional office definitions 112 
(www.who.org) were used to classify countries as European or Non-European. Nine non-113 
European countries participated in the 2015 EBMT survey: Algeria, Iran, Israel, Jordan, 114 
Lebanon, Nigeria, Saudi Arabia, South Africa and Tunisia. Their data (2’776 HSCT in 2’657 115 
patients) from 29 actively transplanting teams makes up 6.6% of the total data set and is 116 
included in all analyses (13).  117 
 118 
Patient and Transplant numbers 119 
Wherever appropriate, patient numbers corresponding to the number of patients receiving a 120 
first transplant and transplant numbers reflecting the total number of transplants performed 121 
are listed. 122 
The term sibling donor includes HLA identical siblings and twins but not siblings with HLA 123 
mismatches. Unrelated donor transplants includes HSCT from unrelated donors with 124 
peripheral blood and marrow as a stem cell source but not cord blood HSCT, In the 2015 125 
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survey we collected separately the numbers of haplo-identical and other family member 126 
HSCT. Haplo-identical being described as any family member with 2 or more loci mismatch 127 
within the loci HLA-A,-B,-C,-DRB1 and -DQB1 in GvH and/or HvG direction. Other family 128 
member donors are those related donors that are mismatched to a lesser degree than a full 129 
haplotype.  Additional non first transplants may include multiple transplants defined as 130 
subsequent transplants within a planned double or triple autologous or allogeneic transplant 131 
protocol, and retransplants (autologous or allogeneic) defined as unplanned HSCT for 132 
rejection or relapse after a previous HSCT.  133 
 134 
Transplant rates 135 
Transplant rates, defined as the total number of HSCT per 10 million inhabitants, were 136 
computed for each country without adjustments for patients who crossed borders and 137 
received their HSCT in a foreign country.  Population numbers were obtained from Eurostats 138 
for 2015 for the European countries, 139 
(http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database) and the US 140 
census bureau database for the non-European countries 141 
(http://www.census.gov/population/international/data/idb/rank.php). 142 
 143 
Analysis 144 
Wherever appropriate the absolute numbers of transplanted patients, transplants or 145 
transplant rates are shown for specific countries, indications or transplant techniques. 146 
Myeloid malignancies include acute myeloid leukemia (AML), myelodysplastic or 147 
myelodysplastic/myeloproliferative neoplasm (MDS/MPN), myeloproliferative neoplasm 148 
(MPN) and chronic myeloid leukemia (CML). Lymphoid malignancies include acute 149 
lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin’s disease (HD), 150 
Non-Hodgkin lymphoma (NHL) and plasma cell disorders (PCD).The non-malignant 151 
disorders include bone marrow failure (BMF), thalassemia, sickle cell disease, primary 152 
immune disease (PID), inherited disease of metabolism (IDM) and auto immune disease 153 
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AID. Others include histiocytosis and other rare disorders not included in the above.  154 
 155 
RESULTS 156 
2015 Data 157 
Participating teams in 2015 158 
Of the 655 teams, 412 (62%) performed both allogeneic and autologous transplants; 227 159 
(35%) restricted their activity to autologous HSCT, and 11 teams (2%) to allogeneic 160 
transplants only. Five teams (1%) reported having performed no transplants in 2015 due to 161 
renovation or temporary closure of the transplant unit.  Of the 655 active centers, 131 (20%) 162 
centers performed transplants on both adult and pediatric patients.  An additional 106 (16%) 163 
centers were dedicated pediatric transplant centers and 417 (64%) centers performed 164 
transplants on adults only.   165 
 166 
Numbers of patients and transplants  167 
In 2015 42’171 transplants were reported in 37’626 patients (first transplant); of these, 168 
17’302 HSCT (41%) were allogeneic and 24’869 (59%) autologous (Table 1).  When 169 
compared with 2014 the total number of transplants increased by 3.3% (2.1% allogeneic 170 
HSCT and 4.1% autologous HSCT) (12).  Furthermore, there were 4’545 second or 171 
subsequent transplants, 1’272 allogeneic and 3’273 autologous.  The total number of 172 
patients transplanted under the age of 18 in both dedicated and joint adult-pediatric units was 173 
4’490 (3’338 allogeneic and 1’152 autologous HSCT). Of these, 3’015 patients (67%, 2’570 174 
allogeneic and 896 autologous) reporting a total of 3’466 transplants were performed in 175 
dedicated pediatric centers.  4’545 transplants were second or multiple transplants.  Among 176 
these 3’273 were autologous, the majority of which were probably part of multiple transplant 177 
programs e.g. as for plasma cell disorders. 1’272 were allogeneic HSCTs mainly to treat 178 
relapse or graft failure.  In addition, 794 HSCTs were reported as allogeneic HSCT after a 179 
previous autologous HSCT and were mainly for lymphoma or plasma cell disorders. 180 
 181 
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Indications 182 
Indications for HSCT in 2015 are listed in detail in table 1.  Main indications were myeloid 183 
malignancies (AML, CML, MDS/MPN and MPN): 9’413 (25% of total; 96% of which were 184 
allogeneic); lymphoid malignancies (ALL, CLL, HD, NHL and PCD): 24’340 (65%; 20% 185 
allogeneic); solid tumors: 1’516 (4%; 3% allogeneic); non-malignant disorders: 2’208 (6%; 186 
90% allogeneic) and others: 149 (0.4%). As seen in previous years, the majority of HSCT for 187 
lymphoid malignancies were autologous, while most transplants for leukemia were performed 188 
using stem cells from allogeneic donors.  Autologous HSCT for non-malignant disorders 189 
predominantly include patients with autoimmune disorders.  190 
 191 
Figures 1a and 1b show as a pie graph the distribution of disease indications for allogeneic 192 
(figure 1a) and autologous (figure 1b) respectively. Of interest, we show that for allogeneic 193 
HSCT AML is the most frequent indication (39%), of these 21% were for patients in CR1, 194 
12% for patients with more advanced disease and 6% for patients with transformed AML, 195 
either therapy related or from MDS/MPN. Compared to 2014, there were increases in 196 
allogeneic HSCT for AML by 7.9% and MPN 3.5% and a major decrease by 28% was seen 197 
in allogeneic HSCT use for CLL (figure 2), dropping from 504 patients in 2011 to 255 in 2015. 198 
Among allogeneic HSCT 6’933 were performed using non myeloablative conditioning. This is 199 
an increase of 1% since in 2014 and is 40% of all allogeneic HSCT. For autologous HSCT 200 
there was an increase in myeloma by 8.1%, and Hodgkin lymphoma by 2.1%, proportions for 201 
most other diseases remained stable.  202 
 203 
Important trends in 2015 include continued increase in patients treated with allogeneic and 204 
autologous HSCT use as shown in supplementary figure 1, and increasing use among 205 
allogeneic HSCT recipients of unrelated donor transplantation (14) although it might appear 206 
that the growth rate is slowing down (supplementary figure 2). Figure 3a shows the continued 207 
use of alternative donor transplantation and among these an impressive increase of the use 208 
of haploidentical donors to 2’012 patients in 2015 across Europe; an increase of 291% since 209 
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2005.  The highest growth is seen in myeloid malignancies 1’008, with lymphoid 210 
malignancies 636, nonmalignant disorders 316 and 52 others. Figure 3b shows that the 211 
growth of haploidentical donor HSCT is seen more in patients with myeloid malignancy, but 212 
also in lymphoid malignancy and nonmalignant disorders although to a lesser degree. 213 
Among myeloid malignancies the majority (n=735) are patients with AML. Of note, there are 214 
equal proportions of patients with AML receiving haploidentical donor HSCT transplanted in 215 
CR1 and with more advanced disease (Figure 3c). Stem cell source for haploidentical donor 216 
HSCT is shown in Figure 3d, peripheral blood is used more frequently than marrow. Figure 217 
3e as well as Figure 3a shows in contrast to haploidentical donor HSCT the decreasing use 218 
of unrelated cord blood as a donor source. As shown in Figure 3e this decrease pertains to 219 
myeloid and lymphoid malignancies but not to nonmalignant disorders where the use of 220 
unrelated cord blood is stable over time. 221 
 222 
Transplant rates 223 
Supplementary figures 3a and 3b show transplant rates by country for allogeneic and 224 
autologous HSCT comparing rates in 2015 on maps of Europe.  Median transplant rates per 225 
10 million inhabitants were 153.1 (range, 4.4 – 460.9) for allogeneic HSCT and 251.8 (range, 226 
1.0 – 759.9) for autologous HSCT in 2015.  For the purpose of this analysis we have grouped 227 
countries according to World Bank income group GNI per capita in USD in 2015, 228 
(http://data.worldbank.org/data-catalog/world-development-indicators).  All European 229 
countries fall within the group of either middle income or high income category, so we 230 
created a third group to split furthermore the high income countries into very wealthy 231 
countries defined as >40'000 USD per capita GNI.  Median transplant rates in 2015 for the 3 232 
groups are: 266, 178, 41 for very high, high and medium income countries (allogeneic HSCT, 233 
transplants per 10 million inhabitants) and 941,525, 178 for autologous HSCT respectively.  234 
Figure 4 shows growth rates in allogeneic and autologous HSCT use by income category as 235 
relative growth i.e. % increase from 2005 to 2015 or as absolute increase in transplant rates 236 
from 2005 to 2015 normalized for size of the population.  Figure 4a and 4b shows that % 237 
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increase is highest for middle income countries (GNI < 12500 USD per capita) for both 238 
allogeneic and autologous HSCT and lowest for the very high income countries.  The higher 239 
income countries had already achieved a high level of transplant rates in 2005.  To the 240 
contrary the absolute growth i.e. increase in access of patients to transplant centers is 241 
highest in the very high income countries in the period of 2005-2015 again for both 242 
allogeneic and autologous HSCT. 243 
 244 
Additional cellular therapies (Table 2) 245 
A total of 35 countries (330 teams) reported having performed 3’882 cellular therapies in 246 
2015.  Of these, 2’940 patients received donor lymphocyte infusions. Indications were graft 247 
enhancement: 803 (27%); residual disease: 410 (14%); relapsed disease: 1’285 (44%) and 248 
per protocol 442 (15%). 249 
Other cellular therapies were given either within the context of a HSCT or not.  The majority 250 
were MSCs given for GvHD treatment (396) of for graft enhancement (45).  74 patients 251 
received MSCs for various other indications.  The largest additional group of cellular 252 
therapies were selected or expanded T cells given to treat infectious complications (119 253 
patients) or for anti-malignant effects (37).  Other cellular therapies including NK cells (14), 254 
TREGs (35), genetically modified T-cells (14), dendritic cells (25) and expanded or 255 
genetically modified hematopoietic stem cells (36) were reported more rarely.  121 patients 256 
received cellular products for purposes of regenerative medicine (15,16). 257 
 258 
DISCUSSION 259 
The EBMT activity survey has been conducted annually since 1990 (6).  The 2010 survey 260 
reported for the first time more than 30’000 patients transplanted in a given year (17), and 261 
more than >40'000 transplants in 2014.  Again transplant numbers continue to increase 262 
unabated across Europe.  263 
HSCT for some indications continues to increase but not for others.  Of interest is decreasing 264 
use of allogeneic HSCT for CLL and a growth in allogeneic HSCT using haploidentical 265 
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donors, an increase over 200% in the last 5 years. The drop in allogeneic HSCT for CLL is 266 
remarkable and reminds us of the drop seen in CML transplants once kinase inhibitors 267 
became available (18,19). Whether this drop is going to be permanent or whether this is 268 
temporary will depend on the long-term results of kinase inhibitors and possibly bcl2 269 
inhibitors developed to treat CLL.  270 
The continuing use of haploidentical donors is impressive, and it becomes apparent that 271 
haploidentical donor HSCT is not only used for advance disease stages but also for early 272 
disease stages as exemplified by AML (figure 3c). The use of peripheral blood as a stem cell 273 
source has surpassed the use of marrow (figure 3d) although the original studies describing 274 
haploidentical donor HSCT with post-transplant cyclophosphamide as GvHD prophylaxis 275 
have been using mainly marrow (20).  The use of unrelated cord blood, a competitor for 276 
alternative donor HSCT when identical siblings and well matched unrelated donors are not 277 
available continues to decrease but only for malignant disorders (21). Cord blood transplant 278 
rates for nonmalignant diseases remains stable, reflecting the practice mainly in pediatric 279 
centers.  280 
We looked at development of transplant technology in countries in Europe by economic 281 
strength of the societies and for this purpose show growth of allogeneic and autologous 282 
HSCT as relative and as absolute growth for countries in the middle, high and very high 283 
income category. We here confirm that the relative growth is more significant in middle 284 
income countries but that the highest absolute growth over the last decade is seen in the 285 
category of very high income countries. This exemplifies that autologous and allogeneic 286 
HSCT remains an expensive technology broadly available in wealthy societies.  287 
We have added data on the use of cellular therapies, most of which is donor lymphocyte 288 
infusions given to treat relapse or residual disease in over 2’900 patients. Other cellular 289 
therapies have been given to over 900 patients, the largest group of which is mesenchymal 290 
stromal cells to treat GvHD. Although we have established confidence in the reported 291 
transplant numbers we cannot exclude a certain degree of underreporting, particularly in the 292 
most advanced fields of cellular therapies of patients included in studies across Europe. 293 
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In conclusion, this year's activity survey shows continued increase in the use of HSCT across 294 
Europe. Some trends are visible and are discussed here. The paper reflects current practice 295 
and results may be useful to health care planning and health policy makers. 296 
 297 
Abbreviations: 298 
AML; acute myeloid leukemia, ALL; acute lymphoblastic leukemia, CML; chronic myeloid 299 
leukemia, MDS/MPN; myelodysplastic or myelodysplastic/myeloproliferative neoplasm, MPN; 300 
myeloproliferative neoplasm, CLL; chronic lymphocytic leukemia, PCD; plasma cell 301 
disorders, HD; Hodgkin’s disease, NHL; Non-Hodgkin lymphoma; BMF; bone marrow failure, 302 
Thal/sickle; thalassemia/sickle cell disease, PID; primary immune disease, IDM; inherited 303 
disease of metabolism, AID; auto immune disease. CR1: first complete remission. 304 
DLI; donor lymphocyte infusions, MSC; mesenchymal stem cells, NK; natural killer cells, 305 
selected/expanded T cells or CIK; cytokine induced killer cells, TREGS; regulatory T cells.306 
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Legend to the tables 
Table 1 
Numbers of hematopoietic stem cell transplants in Europe 2015 by indication, donor type and 
stem cell source. 
 
Table 2 
Numbers of cellular therapies in Europe 2015 by indication, donor type and cell source. 
 
 
Legend to the Figures 
 
Figure 1: Relative proportion of indications for HSCT in Europe in 2015. 
Fig 1a: Proportions of disease indications for allogeneic HSCT in Europe in 2015.  
Fig 1b: Proportions of disease indications for autologous HSCT in Europe in 2015.  
 
Figure 2: The rise and fall in absolute numbers of allogeneic HSCT for CLL in Europe 1990-
2015 
 
Figure 3: Change in the absolute numbers of haploidentical and cord blood HSCT in Europe 
1990 - 2015 
 Fig 3a: Change in donor selection from cord blood HSCT to haploidentical HSCT 
Fig 3b: Increase in the use of haploidentical donors by main indication group. 
Fig 3c: Haploidentical HSCT by AML early disease and advanced disease. 
Fig 3d: Haploidentical HSCT by cell source; bone marrow versus peripheral blood. 
Fig 3e: Trend in the use of unrelated cord blood HSCT by main indication group 
2006-2015. 
 
Figure 4: Effect of income group on transplant activity and transplant rates in 2015. 
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Fig 4a: percentage increase in transplant activity for allogeneic HSCT (top left), 
 increase in transplant rates for allogeneic HSCT (bottom left). 
Fig 4b: percentage increase in transplant activity for autologous HSCT (top right), 
increase in transplant rates for autologous HSCT (bottom right). 
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Figure 1:  Absolute numbers of HSCT activity by transplant type; allogeneic and 
autologous in Europe 1990-2015 
 
Figure 2: Change in donor choice in Europe 1990-2015. Absolute numbers of HLA 
identical sibling, haploidentical family, unrelated and cord blood donors 
 
Figure 3: Transplant rates in Europe (= total number of HSCT per 10 million inhabitants)  
  by participating country in 2015 
 
 Fig 3a: Allogeneic Transplant Rates/per10 million population in 2015 
Fig 3b: Autologous Transplant Rates/per10 million population in 2015 
 
Table 1
TRANSPLANT ACTIVITY 2015
No. of patients 
Autologous T o t a l 
Family Unrelated
HLA-id Twin Haplo >=2MM BM BM + Allo Auto
BM PBPC Cord all BM PBSC BM PBPC Cord BM PBPC cord only PBPC cord
Myeloid malignancies 412 2439 5 9 310 603 28 68 0 525 4425 170 9 410 0 8994 419 9413
Acute myeloid leukemia 290 1750 5 6 208 460 15 52 0 330 2940 133 9 404 0 6189 413 6602
      1st complete remission 201 1077 5 3 100 196 10 29 0 203 1537 79 6 349 0 3440 355 3795
      not 1st complete remission 64 485 0 3 81 199 4 21 0 90 864 37 3 50 0 1848 53 1901
AML therapy related 11 57 0 0 4 18 0 1 0 9 115 6 0 2 0 221 2 223
AML from MDS/MPN 14 131 0 0 23 47 1 1 0 28 424 11 0 3 0 680 3 683
Chronic myeloid leukemia 26 115 0 0 14 12 0 2 0 27 196 6 0 3 0 398 3 401
      chronic phase 14 48 0 0 2 5 0 1 0 14 78 1 0 1 0 163 1 164
      not 1st chronic phase 12 67 0 0 12 7 0 1 0 13 118 5 0 2 0 235 2 237
MDS or MD/MPN 87 442 0 3 68 108 12 9 0 146 971 28 0 3 0 1874 3 1877
MPN 9 132 0 0 20 23 1 5 0 22 318 3 0 0 0 533 0 533
Lymphoid malignancies 338 1410 5 11 222 356 16 41 1 392 1984 114 26 19424 0 4890 19450 24340
Acute lymphatic leukemia 264 641 5 2 101 185 15 27 1 309 851 93 3 81 0 2494 84 2578
      1st complete remission 164 457 0 2 49 92 9 12 1 146 556 43 1 65 0 1531 66 1597
      not 1st complete remission 100 184 5 0 52 93 6 15 0 163 295 50 2 16 0 963 18 981
Chronic lymphocytic leukemia 9 83 0 0 7 13 0 3 0 7 131 2 0 36 0 255 36 291
Plasma cell disorders - MM 6 194 0 2 13 14 0 1 0 20 285 3 5 10856 0 538 10861 11399
Plasma cell disorders - other 0 15 0 2 0 1 0 0 0 2 9 0 0 326 0 29 326 355
Hodgkin's lymphoma 12 130 0 2 55 61 1 2 0 9 166 4 8 2062 0 442 2070 2512
Non Hodgkin lymphoma 47 347 0 3 46 82 0 8 0 45 542 12 10 6063 0 1132 6073 7205
Solid tumors 5 2 1 1 2 19 0 1 0 2 4 1 47 1430 1 38 1478 1516
Neuroblastoma 3 1 1 0 2 12 0 0 0 0 1 1 27 459 1 21 487 508
Soft tissue sarcoma/Ewing 0 0 0 0 0 5 0 1 0 0 2 0 10 205 0 8 215 223
Germinal tumors 0 0 0 0 0 0 0 0 0 0 0 0 1 350 0 0 351 351
Breast cancer 0 0 0 0 0 0 0 0 0 0 0 0 0 29 0 0 29 29
Other solid tumors 2 1 0 1 0 2 0 0 0 2 1 0 9 387 0 9 396 405
Non malignant disorders 648 241 28 4 64 131 72 49 4 419 227 98 9 214 0 1985 223 2208
Bone marrow failure - SAA 185 105 5 3 16 22 11 3 1 124 79 12 0 0 0 566 0 566
Bone marrow failure - other 68 24 4 0 8 20 9 12 1 73 31 11 0 0 0 261 0 261
Thalassemia 148 66 9 1 5 12 17 7 1 55 19 1 1 3 0 341 4 345
Sickle cell disease 92 11 6 0 10 4 3 1 0 14 5 0 0 0 0 146 0 146
Primary Immune deficiencies 130 26 3 0 19 65 27 22 1 120 77 37 2 6 0 527 8 535
Inh. disorders of Metabolism 23 5 1 0 6 7 5 3 0 30 14 35 4 0 0 129 4 133
Auto immune disease 2 4 0 0 0 1 0 1 0 3 2 2 2 205 0 15 207 222
Others 31 10 1 0 8 16 5 1 0 17 27 7 0 26 0 123 26 149
TOTAL PATIENTS 1434 4102 40 25 606 1125 121 160 5 1355 6667 390 91 21504 1 16030 21596 37626
Re/additional transplants 55 257 0 2 96 257 4 12 0 71 497 21 7 3266 0 1272 3273 4545
TOTAL TRANSPLANTS 1489 4359 40 27 702 1382 125 172 5 1426 7164 411 98 24770 1 17302 24869 42171
Allogeneic 
Other family
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Table 2
Number of patients DLI
Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto
GvHD 396 3 29 1 3
Graft enhancement 803 44 1 2 14 5 24
Autoimmune dis. 4 40
Genetic disease 2 1 8
Infection 4 119 6
Malignancy 1 11 1 32 5 1 5 8 4 5 20 19 3
DLI for residual disease 410
DLI for relapse 1285
DLI per protocol 442
Regenerative medicine 16 7 1 3 94
Total 2940 467 48 13 1 168 5 30 5 9 5 5 20 9 0 19 8 33 97
Expanded 
CD34+ cells
Genetically 
modified CD34+ 
cells
OtherMSC NK cells selected/expanded T cells or CIK
Regulatory T 
cells (TREGS)
Genetically 
modified T cells Dendritic cells
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